Becton Dickinson And Company (BDX) closed at $214.52 on November 11, 2026, up 0.9% from the previous close, on volume of 1,478,718 shares (30-day average 1,765,624).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Put Spread | 20-Nov-26190 : 210 P | 800 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
BD to Host Investor Day on December 10, 2026
PRNewswire (Tue, 10-Nov 4:19 PM ET)
Becton Dickinson (BDX) Gets a Sell from Barclays
TipRanks (Tue, 10-Nov 2:36 AM ET)
UBS Keeps Their Buy Rating on Becton Dickinson (BDX)
TipRanks (Mon, 9-Nov 8:55 AM ET)
Bank of America Securities Remains a Hold on Becton Dickinson (BDX)
TipRanks (Sat, 7-Nov 12:36 AM ET)
BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
PRNewswire (Thu, 5-Nov 6:30 AM ET)
PRNewswire (Thu, 5-Nov 6:25 AM ET)
BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
PRNewswire (Wed, 4-Nov 6:50 AM ET)
PRNewswire (Wed, 28-Oct 6:50 AM ET)
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
PRNewswire (Thu, 8-Oct 4:16 PM ET)
BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
PRNewswire (Thu, 8-Oct 6:50 AM ET)
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Becton Dickinson And Company trades on the NYSE stock market under the symbol BDX.
As of November 12, 2026, BDX stock price climbed to $215.87 with 497,946 million shares trading.
BDX has a beta of 0.01, meaning it tends to be less sensitive to market movements. BDX has a correlation of 0.00 to the broad based SPY ETF.
BDX has a market cap of $61.41 billion. This is considered a Large Cap stock.
Last quarter Becton Dickinson And Company reported $5 billion in Revenue and $4.15 earnings per share. This beat revenue expectation by $159 million and exceeded earnings estimates by $.08.
In the last 3 years, BDX traded as high as $251.99 and as low as $140.11.
The top ETF exchange traded funds that BDX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BDX has outperformed the market in the last year with a price return of +39.9% while the SPY ETF gained +12.5%. BDX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.6% and +10.6%, respectively, while the SPY returned -1.0% and -1.5%, respectively.
BDX support price is $211.56 and resistance is $217.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDX shares will trade within this expected range on the day.
